Loading market dashboard
Tivic Health Systems, Inc.
TIVCHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Ticker Symbol to Change from TIVC to VBIO Effective April 28, 2026; Company Advancing Entolimod™ Toward BARDA Funding and Strategic National Stockpile Procurement While Velocity Bioworks CDMO Builds Independent Revenue Base SAN ANTONIO, April 23, 2026 /PRNewswire/ -- Tivic Health Systems, Inc. (Nasdaq: TIVC) today announced it is changing its corporate name to Valion Bio, Inc. and its Nasdaq ticker symbol from TIVC to VBIO, effective at market open on Tuesday, April 28, 2026. The CUSIP number for the company's common stock will remain unchanged.
Tivic Health Systems, Inc. (NASDAQ: TIVC - Get Free Report) Director Sheryle Bolton acquired 10,000 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was purchased at an average price of $1.04 per share, with a total value of $10,400.00. Following the transaction, the director owned 10,000 shares in the
SAN ANTONIO, April 15, 2026 /PRNewswire/ -- Tivic Health Systems, Inc. (Nasdaq: TIVC), a clinical-stage immunotherapeutics company, today announced it has been selected to present at the U.S. Department of War's Tech Watch program on May 7, 2026. The Tech Watch initiative identifies emerging technologies with high-value defense and dual-use applications.
Tivic Health Systems (NASDAQ: TIVC - Get Free Report) and Omnicell (NASDAQ: OMCL - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations. Earnings and Valuation This table compares Tivic
Tivic Health Systems (NASDAQ: TIVC) outlined its strategy to advance what it described as late-stage, "highly de-risked" biopharma assets over the next 12 to 24 months, with a primary focus on Entolimod, a Toll-like receptor 5 (TLR5) agonist. Speaking during the event, company executive Michael said the company is focused on immune therapies intended to improve
Rennova Health (OTCMKTS:RNVA - Get Free Report) and Tivic Health Systems (NASDAQ: TIVC - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends. Analyst Ratings This is a summary
SAN ANTONIO, TX / ACCESS Newswire / March 31, 2026 / Tivic Health Systems, Inc. (Nasdaq:TIVC), a clinical-stage immunotherapeutics company, today announced it has received a formal Request for Information (RFI) from the Ukrainian Ministry of Health. The RFI initiates the formal evaluation of Entolimod™ Tivic's late-stage Toll-like Receptor 5 (TLR5) agonist for potential inclusion in Ukraine's national strategic reserves as a countermeasure against Acute Radiation Syndrome (ARS).
American Well (NYSE: AMWL - Get Free Report) and Tivic Health Systems (NASDAQ: TIVC - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability. Analyst Recommendations This is a summary
Presentation will Cover Recent Corporate Milestones Including Securing Agreement with NIAID SAN ANTONIO, TX / ACCESS Newswire / March 27, 2026 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a clinical-stage immunotherapeutics company, today announced that its newly appointed Chief Executive Officer, Michael K Handley, will deliver a corporate update at the Emerging Growth Virtual Conference taking place April 1-2, 2026. During the virtual conference, Mr.
Armed Forces Radiobiology Research Institute (AFRRI) Will Conduct the Gastrointestinal Acute Radiation Syndrome (GI-ARS) Study SAN ANTONIO, TX / ACCESS Newswire / March 26, 2026 / Tivic Health Systems Inc. (Nasdaq:TIVC), a clinical-stage immunotherapeutics company, today announced it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to sponsor and conduct a series of preclinical studies evaluating Entolimod™ for gastrointestinal acute radiation syndrome (GI-ARS). The program is expected to support Tivic's development strategy for Entolimod™ as a medical countermeasure for acute radiation syndrome (ARS).
Tivic Health Systems, Inc. (TIVC) Q4 2025 Earnings Call Prepared Remarks Transcript
Completes Strategic Transformation into an Immunotherapy Company and Continues to Advance Entolimod Platform Toward Potential Funding Partnerships Conference Call to be Held Today at 1:30 PM PT / 4:30 PM ET SAN ANTONIO, TX / ACCESS Newswire / March 25, 2026 / Tivic Health Systems, Inc. (Nasdaq:TIVC), a development-stage immunotherapy company, today reported financial and operational results for the year ended December 31, 2025, and provided a business update highlighting the company's strategic transformation and focus on the development of its Entolimod™ platform. "2025 was a defining year for Tivic as we marked our transformation into a focused immunotherapy company anchored by Entolimod and its next-generation molecule, Entolasta," said Michael K.
SAN ANTONIO, TX / ACCESS Newswire / March 24, 2026 / Tivic Health Systems (Nasdaq:TIVC) Dear Valued Shareholders, As I assume the role of Chief Executive Officer at Tivic, my immediate priority is to establish a transparent dialogue with you regarding our current standing, our strategic pivot, and the long-term vision we are executing. First, I want to thank the Board of Directors for their confidence and support.
Hims and Hers Health (NYSE: HIMS - Get Free Report) and Tivic Health Systems (NASDAQ: TIVC - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends. Volatility and Risk Hims and
SAN ANTONIO, TX / ACCESS Newswire / March 20, 2026 / Tivic Health Systems, Inc. (Nasdaq:TIVC), a late-stage immunotherapeutics company, today announced that it will report its year-end financial results for 2025 via pre-recorded conference call and webcast on Wednesday, March 25, 2026 at 1:30 PM PT / 4:30 PM ET. Conference Call and Webcast Information Teleconference Details: Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 910220 Webcast Link https://www.webcaster5.com/Webcast/Page/2865/53678 An audio replay of the call will be available for the next 90 days from the investor page on the Tivic website at https://tivichealth.com/investor/.
